Current Market Access to Avsola, Inflectra and Remicade
July
26
While biosimilars Avsola and Inflectra are picking up ground, Remicade is still more advantaged, holding covered or better status for 61% of all insured lives.
NOTE: Access that requires prior authorization and/or step therapy is represented by the abbreviation (PA/ST). 274.0 million lives are covered under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 7/12/21.
Related Posts
November
16
Third-Quarter 2023 Digital Health Funding, Deals Decline, but Promising Areas Exist
Read More
November
16
FDA Approves Multiple Ulcerative Colitis Agents, Bringing New Drugs, Routes of Administration to Class
Read More
November
16
Biosimilar Market Has Had Tremendous Year, With No Signs of Slowing
Read More
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile